Whole Exome Sequencing Market Forecast with Size and Share Analysis 2025 to 2034
Global Whole Exome Sequencing Market Size is valued at USD 1361.18 million in 2022 and is predicted to reach USD 7308.82 million by the year 2031 at a 20.7% CAGR during the forecast period for 2023 to 2031.
Whole Exome Sequencing Market Size, Share & Trends Analysis Report By Product (Instruments, Consumables, Services), By Technology (synthesis, ion semiconductor sequencing), By Workflow (pre-sequencing, sequencing and data analysis), By Application (clinical diagnostics, drug discovery & development, personalized medicine), By End-use, By Region, And Segment Forecasts, 2023 to 2031
The entire exome sequencing has a wide range of clinical applications since it can distinguish between disease-causing mutations or disease variants while identifying exon regions' alterations. The market is expanding due to the increasing use of whole exome sequencing in clinical diagnostics to determine the underlying genetic causes of various disorders. In the upcoming years, the whole exome sequencing industry will rise due to the rising prevalence of chronic diseases and the growing emphasis on finding a cure for untreated medical conditions.
Additionally, the business worked with genomics firm Helix to use their clinical Exome+ sequence analysis tool for the study. Such initiatives give producers of whole exome analysis products and services additional ways to generate income. A cost-effective substitute to conventional sequencing techniques, whole exome sequence analysis also allows for thorough coverage of all genomic areas of medicinal relevance. As opposed to other next-generation sequencing methods, the methodology also has the advantage of quickly identifying rare and low-frequency mutations. Because of this, several end users are implementing whole exome analysis techniques to enhance the sequencing industry. Furthermore, the market for whole exome sequencing is expanding as the infrastructure for providing healthcare continues to advance.
The development of technology for remote surveillance for cancer testing, in order personalized medicine, and other purposes; growing government initiatives aimed at raising awareness of cancer detection and therapy among cancer, Alzheimer's disease, and Miller Syndrome patients; and the heavy emphasis major market players place on providing affordable products.
Recent Developments:
- In February 2023: According to Illumina Inc., the Broad Institute has just received the company's first NovaSeqX Plus machine. The platform will assist parties wishing to access the company's human whole genome product, blended genome/exome product, and sequencing service.
- In May 2022: Thermo Fisher Scientific and The Qatar Genome Programme (QGP), a Qatar Foundation (QF) division, partnered to advance genomic research and clinical applications of predictive genomics in Qatar as a step towards expanding the advantages of precision medicine to Arab populations.
Competitive Landscape:
Some of the Whole Exome Sequencing market players are:
- Agilent Technologies, Inc
- Ambry Genetics
- Azenta US Inc. (GENEWIZ)
- BGI
- CD Genomics
- Eurofins Genomics.
- Hoffmann-La Roche Ltd (Switzerland)
- GENEWIZ (US)
- Illumina Inc. (US)
- Integragen SA (France)
- Knome, Inc. (U.S.)
- Macrogen Inc. (South Korea)
- Novogene Co, Ltd
- Psomagen
- Thermo Fisher Scientific, Inc
Market Segmentation:
The Whole Exome Sequencing market is segmented based on product, technology, workflow, application and end users. The market is segmented as Instruments, Consumables and Services based on product. By technology, the market is segmented into sequencing by synthesis, ion semiconductor sequencing and others. By workflow, the market is segmented into pre-sequencing, sequencing and data analysis. By application, the market is segmented as clinical diagnostics, drug discovery & development, personalized medicine and others. By end users, the market is segmented as academic & research institutes, hospitals & clinics, pharmaceutical & biotechnology companies and others.
Based On End Users, The Hospitals & Clinics Segment Is A Major Contributor In The Whole Exome Sequencing Market
The hospitals & clinics category will hold a major share of the Whole Exome Sequencing market in 2022. The sales revenues generated by various cutting-edge medical institutions primarily fuel medical innovation. The market for medical services is anticipated to expand as awareness and affordability rise, as is already the case in numerous developed nations where healthcare services have a significant positive impact on GDP development.
The Personalized Medicine Segment Witnessed Growth At A Rapid Rate
The personalized medicine segment is projected to grow rapidly in the whole exome sequencing market. Depending on the molecular cause of the condition, personalized medicine seeks to offer each patient a treatment plan that is uniquely designed for them. The previous few years have seen a rise in its popularity. In contrast to traditional medicine, precision medicine is a new field of study called "individualized medicine," which bases healthcare decisions on each patient's genetic profile.
Medical experts may create safer and more efficient treatment plans and medications for various health disorders thanks to advancements in genetics and a deeper understanding of how human genetic composition and health influences development, reaction to treatments, and health. In various ways, precision is advantageous to health and healthcare. The rising incidence of various cancer types, the accessibility of tailored medicine therapy in cancer medications, and a number of other causes are causing this personalized medicine.
The North America Whole Exome Sequencing Market Holds A Significant Revenue Share
The North America Whole Exome Sequencing market position is expected to register the highest market share in revenue shortly. Due to the high frequency of genetic abnormalities, the existence of major market players, and the availability of financing in the public and private sectors. Additionally, advanced research facilities, rising funding for cancer- and genomics-related studies, and widespread use of exome sequencing to detect uncommon illnesses are anticipated to propel market expansion in North America throughout the projected period. In addition, the Asia Pacific region is projected to increase at a prompt rate in the global whole exome sequencing market due to growing concerns about the environment, rapid industrialization, government initiatives, and increasing funding in various industries.
Whole Exome Sequencing Market Report Scope:
| Report Attribute | Specifications |
| Market size value in 2022 | USD 1361.18 Mn |
| Revenue forecast in 2031 | USD 7308.82 Mn |
| Growth rate CAGR | CAGR of 20.7 % from 2023 to 2031 |
| Quantitative units | Representation of revenue in US$ Billion, and CAGR from 2023 to 2031 |
| Historic Year | 2019 to 2022 |
| Forecast Year | 2023-2031 |
| Report coverage | The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
| Segments covered | Type, Type of Project, And Application |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | Thermo Fisher Scientific, Inc.; Illumina, Inc.; Agilent Technologies, Inc.; BGI; Psomagen; Hoffmann-La Roche Ltd; Azenta US Inc. (GENEWIZ); CD Genomics; Novogene Co, Ltd; Eurofins Genomics |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Whole Exome Sequencing Market-
Whole Exome Sequencing Market By Product
- Instruments
- Consumables
- Services
Whole Exome Sequencing Market By Technology
- Sequencing by Synthesis
- ION Semiconductor Sequencing
- Others
Whole Exome Sequencing Market By Workflow
- Pre-sequencing
- Sequencing
- Data Analysis
Whole Exome Sequencing Market By Application
- Clinical Diagnostics
- Drug Discovery & Development
- Personalized Medicine
- Others
Whole Exome Sequencing Market By End-use
- Academic & Research Institutes
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Others
Whole Exome Sequencing Market By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Whole Exome Sequencing Market Size is valued at 1361.18 million in 2022 and is predicted to reach 7308.82 million by the year 2031
Whole Exome Sequencing Market expected to grow at a 20.7% CAGR during the forecast period for 2023-2031
Thermo Fisher Scientific, Inc.; Illumina, Inc.; Agilent Technologies, Inc.; BGI; Psomagen; Hoffmann-La Roche Ltd; Azenta US Inc.